Check for updates

OPEN ACCESS

EDITED BY Noemi Montobbio, University of Genoa, Italy

REVIEWED BY Minh Hoang Gia, Gwangju Institute of Science and Technology, Republic of Korea Shuqiang Wang, Chinese Academy of Sciences (CAS), China

*CORRESPONDENCE Rosanna Turrisi Ize rosanna.turrisi@edu.uniqe.it

RECEIVED 22 December 2023 ACCEPTED 03 September 2024 PUBLISHED 20 September 2024

CITATION

Turrisi R, Verri A and Barla A (2024) Deep learning-based Alzheimer's disease detection: reproducibility and the effect of modeling choices.

Front. Comput. Neurosci. 18:1360095. doi: 10.3389/fncom.2024.1360095

COPYRIGHT

© 2024 Turrisi, Verri and Barla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Deep learning-based Alzheimer's disease detection: reproducibility and the effect of modeling choices

Rosanna Turrisi^{1,2}*, Alessandro Verri^{1,2} and Annalisa Barla^{1,2} for the Alzheimer's Disease Neuroimaging Initiative

¹Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy, ²Machine Learning Genoa (MaLGa) Center, University of Genoa, Genoa, Italy

Introduction: Machine Learning (ML) has emerged as a promising approach in healthcare, outperforming traditional statistical techniques. However, to establish ML as a reliable tool in clinical practice, adherence to best practices in *data handling*, and *modeling design and assessment* is crucial. In this work, we summarize and strictly adhere to such practices to ensure reproducible and reliable ML. Specifically, we focus on Alzheimer's Disease (AD) detection, a challenging problem in healthcare. Additionally, we investigate the impact of modeling choices, including different data augmentation techniques and model complexity, on overall performance.

Methods: We utilize Magnetic Resonance Imaging (MRI) data from the ADNI corpus to address a binary classification problem using 3D Convolutional Neural Networks (CNNs). Data processing and modeling are specifically tailored to address data scarcity and minimize computational overhead. Within this framework, we train 15 predictive models, considering three different data augmentation strategies and five distinct 3D CNN architectures with varying convolutional layers counts. The augmentation strategies involve affine transformations, such as *zoom*, *shift*, and *rotation*, applied either concurrently or separately.

Results: The combined effect of data augmentation and model complexity results in up to 10% variation in prediction accuracy. Notably, when affine transformation are applied separately, the model achieves higher accuracy, regardless the chosen architecture. Across all strategies, the model accuracy exhibits a concave behavior as the number of convolutional layers increases, peaking at an intermediate value. The best model reaches excellent performance both on the internal and additional external testing set.

Discussions: Our work underscores the critical importance of adhering to rigorous experimental practices in the field of ML applied to healthcare. The results clearly demonstrate how data augmentation and model depth—often overlooked factors— can dramatically impact final performance if not thoroughly investigated. This highlights both the necessity of exploring neglected modeling aspects and the need to comprehensively report all modeling choices to ensure reproducibility and facilitate meaningful comparisons across studies.

KEYWORDS

deep learning, Alzheimer's disease, data augmentation, model depth, reproducibility

1 Introduction

Advanced Machine Learning (ML) techniques have proven to be highly effective in healthcare applications, such as cancer detection and prognosis (Cruz and Wishart, 2006; Sajda, 2006; Kourou et al., 2015; Shen et al., 2019; Chaunzwa et al., 2021), heart diseases prediction (Mohan et al., 2019; Palaniappan and Awang, 2008), and neurodegenerative diseases' diagnosis (Pereira et al., 2016; Montolío et al., 2021). However, it is still premature to assert that ML is ready to be employed as a standard in clinical practice. For instance, in Roberts et al. (2021), the authors reviewed thousands of papers on the use of ML to detect COVID-19 and found that none achieved the robustness and reproducibility required for medical use. This issue is not specific to ML methods for COVID-19 detection but involves the entire ML community (Ioannidis, 2005; Pineau et al., 2021), particularly the field of ML in healthcare (Stupple et al., 2019; Beam et al., 2020; Heil et al., 2021). To address this issue, Luo et al. (2016) asked 11 researchers with expertise in biomedical ML to produce a set of rules ensuring that ML models within clinical settings are sufficiently reported. These rules mainly relate to paper writing, providing a checklist for each article section. Although Luo et al. (2016) offers a useful tool for checking final manuscripts, it does not identify specific practices for developing ML methods in healthcare and is often very general when it comes to report ML model details (e.g., identifying if the study is retrospective/prospective and if the prediction task is regression/classification).

In our manuscript, we identify an essential set of practical guidelines, and we highlight the importance of fully adhering to them. To demonstrate this, we present a practical application of ML in healthcare by following these guidelines and demonstrating the impact of modeling choices on the final performance. Specifically, we focus on Deep Learning (DL) for Alzheimer's Disease (AD) diagnosis. AD is the most common type of dementia, impacting over 30 million individuals globally. It is characterized by (i) a pre-symptomatic stage where pathological molecular changes and neuronal dysfunctions occur at brain level, (ii) a prodromal stage identified as mild cognitive impairment (MCI) syndrome; (iii) an early-stage where cognitive symptoms of AD become more evident; (iv) a late stage with overt dementia. This progressive neurodegenerative disorder leads to cognitive and functional decline, impairing daily activities and eventually resulting in death. Hence, timely and accurate diagnosis of AD is crucial for effective treatments. Structural Magnetic Resonance Imaging (MRI) has proven to be a powerful tool for predicting AD due to its ability to visualize detailed brain structures and identify changes associated with the disease, such as hippocampal atrophy (Jack et al., 2000; Van De Pol et al., 2006), cortical thinning (Du et al., 2007), and brain volume loss (Pini et al., 2016).

In this study, we leverage low-resolution MRI scans and address the challenge of discriminating patients with AD from

Cognitively Normal (CN) subjects using a 3D-Convolutional Neural Network (CNN) (LeCun et al., 1995). We combine different data augmentation strategies and CNN depths, creating a total of 15 DL models. We show that these modeling choices can lead to significant variations in prediction accuracy, up to 10%. The best model demonstrates excellent accuracy on the testing set and good properties of generalization to an external dataset. It is worth noting that the proposed approach can be readily extended to other modeling choices and healthcare applications.

The paper is structured as follows. The Materials and Methods section includes the guidelines for ML reliability and reproducibility, and introduces state-of-the-art studies in the AD field. Then, it details data handling and the experimental setup, including modeling challenges and choices made. The Results section evaluates the effect of the modeling choices, comparing augmentation strategies and architectures. The Discussion section relates findings to state-of-the-art studies and illustrates future perspectives.

2 Materials and methods

2.1 Guidelines

To begin, we summarize the general guidelines for reliable and reproducible ML pertaining to two key aspects: *data handling*, and *model design and assessment*.

Data handling (D)

- Data collection/selection should align with the scientific problem at hand (e.g., utilizing cross-sectional data for diagnostic confirmation or longitudinal data for prognostic purposes), avoiding bias and information leakage (Saravanan et al., 2018).
- 2. Data quality should be assessed by identifying missing values and inconsistencies, and improved by applying appropriate imputation and cleaning methods (Lin and Tsai, 2020).
- 3. Data harmonization can be used to compensate for heterogeneous data from different acquisition techniques (Kourou et al., 2018).
- 4. Data augmentation can be employed as a solution for small sample size or unbalanced samples per class, a common case in the biomedical field.
- 5. The whole data handling process should be described in details in order to ensure reproducibility.

Model design and assessment (M)

- 1. The versioned code used for conducting the experiments should be publicly shared to ensure transparency and reproducibility.
- 2. Every decision in the design of the predictive model should be justified, with recognition of uncontrollable factors (Haibe-Kains et al., 2020).
- 3. Details about the samples used in the training/testing split should be disclosed to guarantee benchmarking.
- 4. A well-designed experiment should avoid assessing results on a non-representative testing set. To this aim, resampling strategies (Batista et al., 2004) such as k-fold cross-validation or boosting can be utilized to comprehensively assess the model's performance. Further, models based on random weights

Abbreviations: ML, Machine Learning; DL, Deep Learning; CNN, Convolutional Neural Network; CL, Convolutional Layers; AD, Alzheimer's Disease; MCI, Mild Cognitive Impairment; CN, Cognitive Normal; ADNI, Alzheimer's Disease NEuroimaging Initiative; MRI, Magnetic Resonance Imaging; D, Data handling; M, Model design and assessment.

initialization should be repeated for different trials in order to assess their stability.

- The performance metrics should be chosen according to the specific scientific objectives of the study (Sokolova and Lapalme, 2009; Chicco and Jurman, 2020).
- 6. Testing the model on external datasets is ideal to evaluate its generalization properties (Basaia et al., 2019).

These guidelines are followed throughout the rest of the paper and referenced within the text whenever a rule is applied in the experiments.

2.2 State of the art

AD is a neurodegenerative disease and the most common form of dementia globally, characterized by progressive neurodegeneration, leading to cognitive and functional decline, impaired daily activities, and eventually, death (Wu et al., 2017; Dubois et al., 2016). Brain imaging, particularly MRI scans, plays a crucial role in diagnosing AD by providing detailed insights into the structural brain changes associated with the disease. In recent years, ML models have shown significant potential in utilizing imaging data to improve automated AD diagnosis (Yu et al., 2022) and predict AD-related brain abnormality (Zong et al., 2024). For instance, Zuo et al. (2024) use multiple brain image modalities with an adversarial learning strategy for AD progression prediction and to identify abnormal brain connections. Similarly, Pan et al. (2024) proposes a generative adversarial network with a decoupling module to detect abnormal neural circuits.

As reported in Arya et al. (2023), the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset (Mueller et al., 2005) is the most frequently employed dataset in AD studies based on ML and DL approaches. ADNI comprises heterogeneous datasets collected during different temporal phases (ADNI1, ADNI/GO, ADNI2, and ADNI3), each characterized by varying MRI acquisition protocols. ADN11 includes longitudinal acquisitions on 1.5T and 3T scanners with T1- and T2-weighted sequences; ADNI-GO/ADNI2 contains imaging data acquired at 3T with similar T1-weighted parameters to ADN11; ADNI3 exclusively utilizes MRI obtained from 3T scanners. Further, within a temporal phase, multiple acquisitions are done at different time steps (e.g., baseline, screening, follow up).

The heterogeneity of ADNI allowed for many experimental setups in the literature, with varying results depending on sample size [ranging from hundreds (Liu et al., 2014; Alinsaif and Lang, 2021; Long et al., 2017; Korolev et al., 2017) to thousands (Salehi et al., 2020; Basaia et al., 2019)], images resolution, or sequence type. However, this variability and the lack of a universally recognized benchmark have hindered fair comparisons of published models. Another consequence is that AD studies are more susceptible to information leakage. In Wen et al. (2020), the authors reviewed 32 studies using CNN models for AD diagnosis and found that about 50% of them reported biased results due to data leakage. These factors underscore the essential need for carefully selecting the dataset (D1), reporting details on data processing (D5, M3), taking into account the dataset size (D4, M3, M4) and choosing the model (M2) and the evaluation metrics accordingly (M5). In the rest of the section, we discuss state of the art (SOTA) studies on MRI-based AD classification using ADNI and describe their experimental approaches in relation to the criteria D and M. We emphasize that a systematic review is behind the purpose of this work, which has the scope of highlighting good and bad practices in ML for healthcare.

We considered the studies reported in a recent PRISMA-based review (Arya et al., 2023), selecting 8 articles that used solely MRI scans from ADNI dataset (Mehmood et al., 2021; Li and Yang, 2021; Pan et al., 2020; Alickovic et al., 2020; Korolev et al., 2017; Yue et al., 2019; Xiao et al., 2017; Tong et al., 2014). To increase the sample of DL-based articles, we further considered three SOTA articles (Salehi et al., 2020; Basaia et al., 2019; Ghaffari et al., 2022), for a total of 11 articles. We found that none of them fully adhered to the guidelines listed in the previous section. In particular:

- D1: 73% of studies did not report the ADNI phase, and 91% did not specify the time step (e.g., baseline, follow-up). This information is crucial to ensure that baseline and follow-up data are not mixed, thereby preventing data leakage. Additionally, 27% of studies did not provide information about MRI resolution (i.e., 1.5T or 3T).
- D4: Data augmentation is applied in only 4 papers (Mehmood et al., 2021; Pan et al., 2020; Basaia et al., 2019; Ghaffari et al., 2022). These papers lack important details, such as transformation parameters and the size of the final training set.
- M1: Only the authors in Korolev et al. (2017) provided the code used for data processing and modeling.
- M2: Only 27% of the works considered different model architectures. Additionally, none of the DL approaches explored model depth as a hyperparameter.
- M3: Three articles split the dataset into training/testing following previous work, whereas the remaining ones did not detail the samples in the splits, preventing benchmarking.
- M4: Resampling strategies were not used in 45% of experiments. Furthermore, no DL-based methods tested model robustness to random weight initialization.
- M5: 91% of studies adopted multiple evaluation metrics. However, standard deviation for resampling strategies was reported in only three papers.
- M6: Generalization across datasets was tested and reported in only two articles.

Note that D2 and D3 are not evaluated here as data quality is ensured by ADNI experts and none of the considered studies rely on different acquisition techniques.

The literature review reveals that none of the considered SOTA studies are fully reproducible due to the absence of available validated code, insufficient details about data processing and augmentation, and lack of information about dataset splits and experimental specifics. Furthermore, the reliability of these works is sometimes limited by unrepresentative testing sets and the lack of evaluation on external datasets. It is also interesting to note that the number of employed samples varies from 170 to 1,662, with a median of 433, a mean of 653, and a standard deviation of 495. This, along with the variability in MRI resolution, makes model comparisons unfeasible. Finally, we noted that model depth and data augmentation strategy (in terms of the number of augmented samples and types of transformations) were completely neglected factors. This led us to investigate whether and to what extent these two modeling choices impact the classification task.

TABLE 1 ADNI1 demographic description.

1.5T	CN	AD	
Subjects	307	243	
Age	75.2 ± 7.6	75.9 ± 5.0	
Sex (M/F)	159/148	130/113	
3T	CN	AD	
Subjects	47	33	
Age	75.1 ± 3.9	74.0 ± 8.1	
Sex (M/F)	18/29	11/22	

1.5 and 3T datasets.

2.3 Data

For our experiments, we adopted the ADNI dataset (Mueller et al., 2005) considering T1-weighted 1.5T MRI scans from the ADNI1 data collected during screening, which is the baseline exam. This includes 550 MRI exams from 307 CN subjects and 243 AD patients. Additionally, we used an ADNI1 subset of 80 3T MRI exams as an external testing set, to evaluate the best model in a *domain shift* setting (Buchanan et al., 2021). Table 1 reports demographic details about the two datasets (D1). We recall that MRI exams are three-dimensional data describing the structure of the brain. Figure 1 displays a 2D projection of brain images captured from a CN subject (first row) and an AD patient (second row) on the *sagittal, coronal,* and *axial* planes. All data were preprocessed by ADNI experts, ensuring data quality and harmonization (D2, D3; more information in Supplementary Section 1).

2.3.1 Data augmentation (D4)

Data augmentation is a common procedure that simultaneously addresses data scarcity and creates a model invariant to a given set of transformations (Shorten and Khoshgoftaar, 2019). Different augmentation strategies can result in varied training sets, affecting model performance and computational cost. In this study, the original set is augmented by applying, separately or simultaneously, *zoom*, *shift*, and *rotation* transformations, as shown in Figure 2 (see Supplementary Section 1.3 for details on the transformation parameters). To study the effect of different transformations and sample sizes on model performance, we compared the following three data augmentation strategies:

- **Strategy (A)**. To each image, we simultaneously apply all the transformations (i.e., a zoom by a random factor, a random shift, and a rotation by a random angle). The size of the augmented data will match the number of training samples *N*.
- **Strategy (B)**. To each image, we separately apply each transformation, generating three different distorted images. The size of the augmented data will be three times the number of training samples, *3N*.
- Strategy (C). To each image, we simultaneously apply all the transformations, as in strategy A. We repeat the process three

times so that the number of augmented samples matches the one of strategy B (3N).

Therefore, strategies (A) and (C) rely on the same procedure, while strategies (B) and (C) generate the same number of samples. Although other augmentation techniques (e.g., color transformation, adding noise, and random erasing) may be beneficial, a comprehensive study of data augmentation is beyond the scope of this work. Instead, our goal is to investigate whether and how slight variations in data augmentation choices, often underestimated, impact model performance. In order to avoid data leakage (Wen et al., 2020), data augmentation is performed only on the training set after dataset split, leaving validation and testing sets at the original sample size.

2.3.2 Data processing (D5)

As already noted, ADNI images were collected with different protocols and scanning systems, hence they are very heterogeneous in size, see Table 2. To enable the use of ML methods, it is necessary to select a common volume size. This choice, often left unexplained in literature, defines fundamental characteristics of the pipeline, such as the amount of information contained in the image and the input space dimension, on which model choice and computational burden depend.

In our experiments, images are downsized to $96 \times 96 \times 73$. The principle guiding this choice derives from computational issues. We first reduced the image dimension, rescaling the image by 50% along all dimensions, and we then resized images to match the smallest one. An alternative strategy may be zero-padding to match the biggest image, but this would increase memory requirements. Finally, intensity normalization was applied omitting the zero intensity voxels from the calculation of the mean. This procedure allows having homogeneous data with a fixed size. Note that we do not select any Region Of Interest (ROI) (Long et al., 2017) within the images. Although this setup challenges the classification task, it eliminates the typically laborious and time-consuming feature engineering process.

2.4 Experimental setup

2.4.1 Guide to the model choice (M2)

Choosing the optimal DL model is not straightforward, as the vast numbers of network and training parameters makes a "bruteforce" model selection approach unfeasible. Here, we illustrate the model choices made a priori based on the issues posed by the examined task.

2.4.1.1 Type of data

Working with 3D images presents computational and memory challenges. As a solution, several studies in the literature adopt three 2D projections of the MRI. Nevertheless, this approach requires three separate models, leading to increased overall wallclock time. Moreover, extracting features from the 2D projections may result in the loss of crucial volumetric information and a simplified representation of the studied phenomenon. In this work, we adopted a 3D CNN that directly extracts volumetric features.



2.4.1.2 Limited amount of data

To overcome the limited dataset size, we implemented the following strategies aimed at controlling model complexity and preventing overfitting: data augmentation; adding an ℓ_2 penalty; and limiting the number of filters per layer. The latter method resulted in a substantial parameter reduction across the network. For instance, in a 2-layer CNN with $3 \times 3 \times 3$ filters, reducing the number of filters to 32 to 8 in the first layer and from 64 to 16 in the second layer (25% of the initial values) leads to a considerable reduction of 93% in the number of learnable parameters (from 56,256 to 3,696).

2.4.1.3 Memory capacity

3D models usually require a huge amount of memory capacity, that depends both on the input dimension and the model size. To reduce the required memory: i) we re-scaled the images to halve the data dimension; ii) we used stochastic gradient descent with a batch size that balances the memory cost while retaining a representative subset; iii) we balanced the number of filters and the batch size to reduce the computational burden of the activation layer.

2.4.2 Model details

We report experiments on the CN/AD binary classification. A preliminary analysis, performed on 1.5T MRI data with a standard training/validation/test split (75%/15%/10%), denoted a very high variance due to the limited sample size of the testing set. For this

reason, to guarantee a correct assessment of model performance and stability, we set up a stratified-K-fold cross-validation loop. We set K = 7, from Fold 0 to Fold 6 (training/validation/test, with a proportion of 70%/15%/15%), that ensures having enough data for the learning phase (M4). All folds were fully balanced, except for Fold 6 which had an unbalanced ratio between AD and CN samples as the total amount of samples per class do not match exactly. We further tested our model on the external dataset of 3T MRI scans (M6). Note that this task is particularly challenging because: i) the evaluation is subject to the domain shift problem, and ii) the training MRI scans have half the resolution of the external MRI exams.

We adopted as baseline network an architecture with 4 Convolutional Layers (CL) followed by a fully-connected layer, as depicted in Figure 3. We will refer to this architecture as 4 CL model. To investigate the optimal CNN depth, we inserted additional convolutional layers without pooling operations so that the number of layers is the only factor impacting in the model. Specifically, we added 2, 4, 6 and 8 convolutional layers in correspondence to the arrows of Figure 3. We refer to these models as 6 CL, 8 CL, 10 CL, and 12 CL. For instance, in the 10 CL architecture 6 convolutional layers are added to the 4 CL baseline: two layers are inserted in correspondence of the first and second arrows, and one layer in correspondence of the third and fourth arrows. Additional details on network and training parameters can be found in the Supplementary Section 2. In order to test model stability to initial random weights, each model was run 10 times



(M4). Model selection was performed based on accuracy. The best one is further analyzed based on Confusion Matrix, Precision, Recall, F1-score, AUC and AUCPRC (M5).

All the experiments were conducted using Python version 3.8 and PyTorch 1.12.1, running on a Tesla K40c GPU. Samples identifiers and the Python code necessary to reproduce the experiments are available on GitHub (M1, M3).

3 Results

In the following, we compare 15 models obtained by combining different augmentation strategies with varying network depths, then we illustrate in detail the results of the best model. Results based on not-augmented data are not reported, as they were substantially worse than the ones obtained by using augmentation.

3.1 Architecture and augmentation choice

We assessed the optimal architecture and augmentation strategy based on the accuracy on the validation set, which is shown in Figure 4. To verify the impact of these factors on the classification task, we performed a statistical analysis of the results obtained by the different models. Initially, we used the Shapiro-Wilk test (Shapiro and Wilk, 1965) to assess the normality of our data, which revealed that the data were not normally distributed. Consequently, we adopted a non-parametric approach to determine significant differences in models' performance. Specifically, we applied the Kruskal-Wallis test (Kruskal and Wallis, 1952) to compare performance across the 15 models. This analysis yielded a statistically significant difference (p-value = 7.45e-07), indicating that the classification task varies significantly among models with different augmentation strategies and network depth.

3.1.1 Data augmentation

Strategy (A) (in yellow) considerably underperforms Strategy (B) (in green), regardless of the CNN architecture used. This can be attributed to the lower number of samples in the augmented data. Surprisingly, Strategies (A) and (C) (in fuchsia) achieve very similar accuracy for a higher number of layers. Finally,

TABLE 2 1.5 T1-weighted MRI scans.

MRI size	CN	AD	Total
$256 \times 256 \times 184$	8	8	16
$256 \times 256 \times 170$	40	34	74
$256 \times 256 \times 160$	4	0	4
256 × 256 × 166	97	82	179
$256 \times 256 \times 162$	0	1	1
$192 \times 192 \times 160$	117	86	203
$256 \times 256 \times 146$	1	0	1
256 × 256 × 161	2	0	2
$256 \times 256 \times 180$	38	32	70

Number of CN and AD MRI scans grouped by size.

although Strategies (B) and (C) generate the same amount of data, Strategy (B) outperforms Strategy (C) across all network depths. To validate these findings, we repeated the Kruskal-Wallis test comparing models using strategy (A), (B), and (C), for each architecture. All tests resulted in p-values less than 0.05, confirming significant differences in performance across different augmentation strategies. Furthermore, as Strategy (B) resulted in the most effective data augmentation approach, we conducted additional statistical analysis on it. Specifically, we used the Conover-Iman test (Conover and Iman, 1979) for pairwise comparison between models based on strategy (B) and those employing different data augmentation strategies. Results revealed a significant difference between strategy (B) and strategy (A) for all network depth, and between strategy (B) and strategy (C) for the 8 CL, 10 CL, and 12 CL architectures. These outcomes underscore the superiority of strategy (B) across all tested architectures, and demonstrate that applying affine transformations separately is more effective than applying them simultaneously.

3.1.2 Network depth

The accuracy curves for all augmentation methods show a similar pattern: the best results are obtained for intermediate amounts of layers, while accuracy decreases for higher numbers of convolutional layers. The same behavior can be observed in Figure 5 where we report for each cross-validation fold the distribution of accuracy in the 10 trials. Using the Kruskal-Wallis test, we found that these differences across architectures were significant when using strategies (A) and (B).

The **8** CL model with strategy (B) emerges as the best-performing combination, exhibiting greater stability within



3D-CNN architecture. Architecture of the **4 CL** baseline network, composed by four blocks of a convolutional and pooling layers, followed by a fully connected (FC) layer. The total number of features (8 * *i*) in the *i*-th convolutional layer is reported above each layer, whereas the filter dimension is reported below. In the experiments, we consider other four extended versions of the baseline architecture (6CL, 8CL, 10CL, 12CL) duplicating once or twice the convolutional layer preceding the arrows.



FIGURE 4

Models accuracy at varying of architecture depth and augmentation strategies. Comparison among the proposed CNN-based architectures with the three augmentation strategies, in terms of median accuracy on the validation set. The *y*-axis reports the model accuracy distribution on the 10 trials (%) and the *x*-axis presents varying augmentation strategies (A), (B), and (C) in 5 blocks—one for each CNN architecture.



augmentation strategies (4CL, 6CL, 8CL, 10CL, 12CL). Each subplot reports the model accuracy on all 7-fold splits. Specifically, the y-axis reports the accuracy distribution on the 10 trials (%) for each fold (x-axis). The best model [8 CL, **(B)**] is highlighted with a red border.

and across folds compared to the other combinations. Further details and specific results of the statistical analysis are available in the Supplementary material.

3.2 Best model performance and insight

The combination of a CNN with 8 convolutional layers and the (B) augmentation strategy [8 CL, (B)] turned out to be the best model, reaching an accuracy of $87.21 \pm 0.88\%$ on the validation set and $81.95 \pm 1.26\%$ on the testing set.

A complete evaluation of this model is reported in Figure 6: left panel reports mean and standard deviation for Precision, Recall, F1-score, AUC and AUCPRC of CN and AD classes over the 7 folds; right panel shows the Confusion matrix obtained by counting True Positive, True Negative, False Positive, and False Negative scores over the 7 folds. Figure 7 gives an insight on the layers behavior and how they are learning the optimal model. The Left Panel displays the learned filters of every convolutional layer for one AD patient on the three considered median planes, i.e., *sagittal, coronal* and *axial*. It is clear that the filters capture more abstract features at increasing depth values. Panel (b) presents, for each convolutional



Evaluation of the [8 CL, (B)] model on the testing set. (Left) Complete evaluation of the model on CN and AD classes averaged over the 7 folds. (Right) Confusion matrix of the classification results counted over the 7 folds.



layer, the layer outputs (*embeddings*) of training and test samples projected on a two-dimensional plane through tdistributed Stochastic Neighbor Embedding (t-SNE) (Van der Maaten and Hinton, 2008). Both projections show that the embeddings are more evidently clustered as the number of layers increases.

To further understand the properties and limits of the (8 CL, (B)) model, we assessed the effect of dropout, finding that it does not improve its performance (details in Supplementary Section 3.2). Also, we tested the model on an external dataset of 3T MRI scans, obtaining an accuracy of 71% and an AUC of 0.76 (a complete evaluation can be found in Supplementary Section 3.3).

4 Discussion

In this paper, we summarized a list of 5 items concerning data handling (D) and 6 items on model design and assessment (M), outlining the criteria that should be adhered to in order to ensure reliability, robustness, and reproducibility in ML for healthcare. Based on these criteria, we constructed an experimental pipeline for MRI-based binary classification of AD vs. CN subjects. Specifically, the experiments were conducted on a pre-processed subset of the ADNI dataset, consisting of 1.5T MRI scans collected during the screening ADNI1 phase (D1). This subset, previously pre-processed by ADNI experts, ensures high data quality (D2) and harmonization (D3). Although the dataset is balanced, its size is limited. To address potential overfitting and ensure reliable results, data augmentation (D4), model complexity reduction (M2), and resampling (M4) strategies were employed. All these aspects are thoroughly discussed (D5). The list of selected samples was made publicly available to enable benchmarking in further studies (M3), along with the Python code (M1).

Additionally, we thoroughly investigated the combined impact of data augmentation strategies (by varying the number of augmented data and the application of transformations) and architecture depth (M2), resulting in a total of 15 models. As reported in Section 2.2, these factors are often neglected in the literature, which typically aims to generate the largest possible number of augmented data and use state-of-the-art architectures (even when very large). Our findings demonstrate that improper settings for these experimental aspects can drastically hamper model performance, reducing accuracy by up to 10 points. Results showed that, independently of the adopted architecture, Strategy (B) always outperformed the others. As strategies (B) and (C) leverage the same amount of training samples, these results suggest that applying the affine transformations separately may help the model build invariance to each of them. Interestingly, strategies (A) and (C) show similar performances for intermediate-to-large models, even though strategy (A) relies on only one-third of the samples generated by strategy (C). We recall that Strategy (A) adopts the same combination of transformations as Strategy (B). This may indicate that the way transformations are combined and applied to the original data has a greater impact than the augmented dataset size itself. Future work will extend this investigation to other data augmentation strategies, including different types of transformation (e.g., color space transformations, Kernel filters, random erasing).

For all augmentation approaches, we found that the curve of the model accuracy at increasing depths tends to be a concave function, reaching the maximum for an intermediate depth value. Although the widespread notion for which deeper neural networks better generalize in a general framework, this result is in line with other studies (Zhang et al., 2021; Vento and Fanfarillo, 2019) in which authors showed that smaller models perform better when only a limited amount of data is available, as they are less subject to overfitting. Although we did not test them, this observation may extend to other SOTA architectures. Indeed, our 8 CL CNN has 220k trainable parameters, while SOTA architectures are typically much larger. For example, ResNet18, ResNet50, and ResNet101 (He et al., 2016) consist of 11.7M, 25.6M, and 44.5M parameters, respectively. The smallest Vision Transformer model (ViT-Base) (Dosovitskiy et al., 2020) includes 86M parameters. EfficientNet-B1 (Tan and Le, 2019) and MobileNetV2 (Sandler et al., 2018), considered among the smallest SOTA architectures, have 7.8M and 3.5M parameters, respectively. Using larger SOTA models may be more effective when pre-trained to leverage transfer learning. However, it is important to note that the vast majority of pretrained models have been trained on natural 2D images, and they are not immediately usable in the context of medical 3D scans. Future work will delve into these aspects.

The best model we identified is the combination of a CNN with 8 convolutional layers and the (B) augmentation strategy [8 CL, (B)]. The model accuracy in validation and testing is $87.21 \pm 0.88\%$ and $81.95 \pm 1.26\%$, respectively, which is 4.2% increase in accuracy with respect to [4 CL, (B)] model. Also, Figure 5 shows how [8 CL, (B)] is more stable than all other models with respect to both cross-validation folds and training trials. These results appear in line with current SOTA studies relying on similar datasets. For instance, Pan et al. (2020) reach 84% of accuracy by using 499 1.5T MRI scans, and Xiao et al. (2017) obtain 85.7% using a dataset of 654 1.5T MRI images. Similarly to our work, Korolev et al. (2017) train a 3D-CNN model on 231 samples, showing 79% of accuracy. Nonetheless, we argue that a true comparison is not completely feasible as other works employ different datasets and data types, the number of samples varies both in training and testing sets, experimental designs are very heterogeneous and, most importantly, performance is always assessed on one trial, without any variability estimation. As an additional evaluation, we tested the best model in a domain shift context (M6), i.e., on 3T MRI data, reaching 71% of accuracy. We remark that this is a very challenging task as the image resolution deeply differs from the one in the training set.

To the best of our knowledge, this is the first work in the AD domain to delve into these modeling aspects and quantify their impact on performance estimation. Future work will extend this analysis to other architectures, different data augmentation transformations, and to a multi-class classification setting that includes MCI subjects.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://adni.loni.usc.edu/data-samples/access-data/.

Ethics statement

The studies involving humans were approved by Albany Medical Center Committee on Research Involving Human Subjects Institutional Review Board, Boston University Medical Campus and Boston Medical Center Institutional Review Board, Butler Hospital Institutional Review Board, Cleveland Clinic Institutional Review Board, Columbia University Medical Center Institutional Review Board, Duke University Health System Institutional Review Board, Emory Institutional Review Board, Georgetown University Institutional Review Board, Health Sciences Institutional Review Board, Houston Methodist Institutional Review Board, Howard University Office of Regulatory Research Compliance, Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, Indiana University Institutional Review Board, Institutional Review Board of Baylor College of Medicine, Jewish General Hospital Research Ethics Board, Johns Hopkins Medicine Institutional Review Board, Lifespan - Rhode Island Hospital Institutional Review Board, Mayo Clinic Institutional Review Board, Mount Sinai Medical Center Institutional Review Board, Nathan Kline Institute for Psychiatric Research and Rockland Psychiatric Center Institutional Review Board, New York University Langone Medical Center School of Medicine Institutional Review Board, Northwestern University Institutional Review Board, Oregon Health and Science University Institutional Review Board, Partners Human Research Committee Research Ethics, Board Sunnybrook Health Sciences Centre, Roper St. Francis Healthcare Institutional Review Board, Rush University Medical Center Institutional Review Board, St. Joseph's Phoenix Institutional Review Board, Stanford Institutional Review Board, The Ohio State University Institutional Review Board, University Hospitals Cleveland Medical Center Institutional Review Board, University of Alabama Office of the IRB, University of British Columbia Research Ethics Board, University of California Davis Institutional Review Board Administration, University of California Los Angeles Office of the Human Research Protection Program, University of California San Diego Human Research Protections Program, University of California San Francisco Human Research Protection Program, University of Iowa Institutional Review Board, University of Kansas Medical Center Human Subjects Committee, University of Kentucky Medical Institutional Review Board, University of Michigan Medical School Institutional Review Board, University of Pennsylvania Institutional Review Board, University of Pittsburgh Institutional Review Board, University of Rochester Research Subjects Review Board, University of South Florida Institutional Review Board, University of Southern, California Institutional Review Board, UT Southwestern Institution Review Board, VA Long Beach Healthcare System Institutional Review Board, Vanderbilt University Medical Center Institutional Review Board, Wake Forest School of Medicine Institutional Review Board, Washington University School of Medicine Institutional Review Board, Western Institutional Review Board, Western University Health Sciences Research Ethics Board, and Yale University Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

Writing RT: _ review & editing, Writing original draft, Visualization, Validation, Methodology, Investigation, Formal analysis. AV: Writing review & editing, Writing original draft. AB: Writing review & editing, Writing original _ draft, Supervision.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Rosanna Turrisi was supported by a research fellowship funded by the DECIPHER-ASL-Bando PRIN 2017 grant (2017SNW5MB-Ministry of University and Research, Italy).

Acknowledgments

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: ADNI Acknowledgment List.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor NM declared а shared affiliation with the authors the parent at time of review.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncom. 2024.1360095/full#supplementary-material

References

Alickovic, E., Subasi, A., and Initiative, A. D. N. (2020). "Automatic detection of alzheimer disease based on histogram and random forest," in CMBEBIH 2019: Proceedings of the International Conference on Medical and Biological Engineering, 16-18 May 2019, Banja Luka, Bosnia and Herzegovina (Cham: Springer), 91-96.

Alinsaif, S., and Lang, J. (2021). 3d shearlet-based descriptors combined with deep features for the classification of alzheimer's disease based on MRI data. *Comput. Biol. Med.* 138:104879. doi: 10.1016/j.compbiomed.2021.104879

Arya, A. D., Verma, S. S., Chakarabarti, P., Chakrabarti, T., Elngar, A. A., Kamali, A.-M., et al. (2023). A systematic review on machine learning and deep learning techniques in the effective diagnosis of alzheimer's disease. *Brain Informat.* 10:17. doi: 10.1186/s40708-023-00195-7

Basaia, S., Agosta, F., Wagner, L., Canu, E., Magnani, G., Santangelo, R., et al. (2019). Automated classification of alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. *NeuroImage: Clini*. 21:101645. doi: 10.1016/j.nicl.2018.101645

Batista, G. E., Prati, R. C., and Monard, M. C. (2004). A study of the behavior of several methods for balancing machine learning training data. *ACM SIGKDD Explorat. Newslett.* 6, 20–29. doi: 10.1145/1007730.1007735

Beam, A. L., Manrai, A. K., and Ghassemi, M. (2020). Challenges to the reproducibility of machine learning models in health care. *JAMA* 323, 305-306. doi: 10.1001/jama.2019.20866

Buchanan, C. R., Mu noz Maniega, S., Valdés Hernández, M. C., Ballerini, L., Barclay, G., Taylor, A. M., et al. (2021). Comparison of structural mri brain measures between 1.5 and 3 t: Data from the lothian birth cohort 1936. *Hum. Brain Mapp.* 42, 3905–3921. doi: 10.1002/hbm.25473

Chaunzwa, T. L., Hosny, A., Xu, Y., Shafer, A., Diao, N., Lanuti, M., et al. (2021). Deep learning classification of lung cancer histology using ct images. *Sci. Rep.* 11, 1–12. doi: 10.1038/s41598-021-84630-x

Chicco, D., and Jurman, G. (2020). The advantages of the matthews correlation coefficient (MCC) over f1 score and accuracy in binary classification evaluation. *BMC Genom.* 21, 1–13. doi: 10.1186/s12864-019-6413-7

Conover, W. J., and Iman, R. L. (1979). *Multiple-Comparisons Procedures*. Los Alamos, NM: Los Alamos National Lab. (LANL).

Cruz, J. A., and Wishart, D. S. (2006). Applications of machine learning in cancer prediction and prognosis. *Cancer Inform.* 2:117693510600200030. doi: 10.1177/117693510600200030

Dosovitskiy, A., Beyer, L., Kolesnikov, A., Weissenborn, D., Zhai, X., Unterthiner, T., et al. (2020). An image is worth 16x16 words: transformers for image recognition at scale. *arXiv [Preprint]*. arXiv:2010.11929. doi: 10.48550/arXiv.2010.11929

Du, A.-T., Schuff, N., Kramer, J. H., Rosen, H. J., Gorno-Tempini, M. L., Rankin, K., et al. (2007). Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. *Brain* 130, 1159–1166. doi: 10.1093/brain/awm016

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., et al. (2016). Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. *Alzheimer's & Dement.* 12, 292–323. doi: 10.1016/j.jalz.2016.02.002

Ghaffari, H., Tavakoli, H., and Pirzad Jahromi, G. (2022). Deep transfer learningbased fully automated detection and classification of Alzheimer's disease on brain mri. *Br. J. Radiol.* 95:20211253. doi: 10.1259/bjr.20211253

Haibe-Kains, B., Adam, G. A., Hosny, A., Khodakarami, F., Massive Analysis Quality Control (MAQC) Society Board of Directors, Waldron, L., et al. (2020). Transparency and reproducibility in artificial intelligence. *Nature* 586, E14–E16. doi: 10.1038/s41586-020-2766-y

He, K., Zhang, X., Ren, S., and Sun, J. (2016). "Deep residual learning for image recognition," in *Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition* (Las Vegas, NV: IEEE), 770–778. doi: 10.1109/CVPR.2016.90

Heil, B. J., Hoffman, M. M., Markowetz, F., Lee, S.-I., Greene, C. S., and Hicks, S. C. (2021). Reproducibility standards for machine learning in the life sciences. *Nat. Methods* 18, 1132–1135. doi: 10.1038/s41592-021-01256-7

Ioannidis, J. P. (2005). Why most published research findings are false. *PLoS Med.* 2:e124. doi: 10.1371/journal.pmed.0020124

Jack Jr, C. R., Petersen, R. C., Xu, Y., O'brien, P., Smith, G. E., Ivnik, R. J., et al. (2000). Rates of hippocampal atrophy correlate with change in clinical status in aging and ad. *Neurology* 55, 484–490. doi: 10.1212/WNL.55.4.484

Korolev, S., Safiullin, A., Belyaev, M., and Dodonova, Y. (2017). "Residual and plain convolutional neural networks for 3d brain MRI classification," in 2017 IEEE 14th International Symposium on Biomedical Imaging (ISBI 2017) (Melbourne, VIC: IEEE), 835–838.

Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., and Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. *Comput. Struct. Biotechnol. J.* 13, 8–17. doi: 10.1016/j.csbj.2014.11.005

Kourou, K. D., Pezoulas, V. C., Georga, E. I., Exarchos, T. P., Tsanakas, P., Tsiknakis, M., et al. (2018). Cohort harmonization and integrative analysis from a biomedical engineering perspective. *IEEE Rev. Biomed. Eng.* 12, 303–318. doi: 10.1109/RBME.2018.2855055

Kruskal, W. H., and Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47, 583–621. doi: 10.1080/01621459.1952.10483441

LeCun, Y., and Bengio, Y. (1995). "Convolutional networks for images, speech, and time series," in *The Handbook of Brain Theory and Neural Networks*, ed. M. A. Arbib (MIT press), 3361.

Li, Q., and Yang, M. Q. (2021). Comparison of machine learning approaches for enhancing Alzheimer's disease classification. *PeerJ* 9:e10549. doi: 10.7717/peerj.10549

Lin, W.-C., and Tsai, C.-F. (2020). Missing value imputation: a review and analysis of the literature (2006-2017). Artif. Intellig. Rev. 53, 1487–1509. doi: 10.1007/s10462-019-09709-4

Liu, S., Liu, S., Cai, W., Pujol, S., Kikinis, R., and Feng, D. (2014). "Early diagnosis of alzheimer's disease with deep learning," in 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI) (Beijing: IEEE), 1015–1018.

Long, X., Chen, L., Jiang, C., Zhang, L., and Initiative, A. D. N. (2017). Prediction and classification of alzheimer disease based on quantification of mri deformation. *PLoS ONE* 12:e0173372. doi: 10.1371/journal.pone.0173372

Luo, W., Phung, D., Tran, T., Gupta, S., Rana, S., Karmakar, C., et al. (2016). Guidelines for developing and reporting machine learning predictive models in biomedical research: a multidisciplinary view. *J. Med. Internet Res.* 18:e323. doi: 10.2196/jmir.5870

Mehmood, A., Yang, S., Feng, Z., Wang, M., Ahmad, A. S., Khan, R., et al. (2021). A transfer learning approach for early diagnosis of alzheimer's disease on mri images. *Neuroscience* 460, 43–52. doi: 10.1016/j.neuroscience.2021.01.002

Mohan, S., Thirumalai, C., and Srivastava, G. (2019). Effective heart disease prediction using hybrid machine learning techniques. *IEEE Access* 7, 81542–81554. doi: 10.1109/ACCESS.2019.2923707

Montolío, A., Martín-Gallego, A., Cegonino, J., Orduna, E., Vilades, E., Garcia-Martin, E., et al. (2021). Machine learning in diagnosis and disability prediction of multiple sclerosis using optical coherence tomography. *Comput. Biol. Med.* 133:104416. doi: 10.1016/j.compbiomed.2021.104416

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., et al. (2005). The Alzheimer's disease neuroimaging initiative. *Neuroimaging Clin. N. Am.* 15:869. doi: 10.1016/j.nic.2005.09.008

Palaniappan, S., and Awang, R. (2008). "Intelligent heart disease prediction system using data mining techniques," in 2008 IEEE/ACS International Conference on Computer Systems and Applications (Doha: IEEE), 108–115.

Pan, D., Zeng, A., Jia, L., Huang, Y., Frizzell, T., and Song, X. (2020). Early detection of alzheimer's disease using magnetic resonance imaging: a novel approach combining convolutional neural networks and ensemble learning. *Front. Neurosci.* 14:501050. doi: 10.3389/fnins.2020.00259

Pan, J., Zuo, Q., Wang, B., Chen, C. P., Lei, B., and Wang, S. (2024). Decgan: Decoupling generative adversarial network for detecting abnormal neural circuits in Alzheimer's disease. *IEEE Trans. Artif. Intellig.* doi: 10.1109/TAI.2024.3416420

Pereira, C. R., Weber, S. A., Hook, C., Rosa, G. H., and Papa, J. P. (2016). "Deep learning-aided parkinson's disease diagnosis from handwritten dynamics," in 2016 29th SIBGRAPI Conference on Graphics, Patterns and Images (SIBGRAPI) (Sao Paulo: IEEE), 340-346.

Pineau, J., Vincent-Lamarre, P., Sinha, K., Larivière, V., Beygelzimer, A., d'Alché Buc, F., et al. (2021). Improving reproducibility in machine learning research: a report from the neurips 2019 reproducibility program. *J. Mach. Learn. Res.* 22, 7459–7478.

Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., et al. (2016). Brain atrophy in alzheimer's disease and aging. *Ageing Res. Rev.* 30:25–48. doi: 10.1016/j.arr.2016.01.002

Roberts, M., Driggs, D., Thorpe, M., Gilbey, J., Yeung, M., Ursprung, S., et al. (2021). Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and ct scans. *Nat. Mach. Intellig.* 3, 199–217. doi: 10.1038/s42256-021-00307-0

Sajda, P. (2006). Machine learning for detection and diagnosis of disease. *Annu. Rev. Biomed. Eng.* 8, 537–565. doi: 10.1146/annurev.bioeng.8.061505.095802

Salehi, A. W., Baglat, P., Sharma, B. B., Gupta, G., and Upadhya, A. (2020). "A CNN model: earlier diagnosis and classification of alzheimer disease using MRI," in 2020 International Conference on Smart Electronics and Communication (ICOSEC) (Trichy: IEEE), 156–161.

Sandler, M., Howard, A., Zhu, M., Zhmoginov, A., and Chen, L.-C. (2018). "Mobilenetv2: Inverted residuals and linear bottlenecks," in *Proceedings of the IEEE* Conference on Computer Vision and Pattern Recognition (Salt Lake City, UT: IEEE), 4510–4520.

Saravanan, N., Sathish, G., and Balajee, J. M. (2018). Data wrangling and data leakage in machine learning for healthcare. *JETIR*. 5, 553–557.

Shapiro, S. S., and Wilk, M. B. (1965). An analysis of variance test for normality (complete samples). *Biometrika* 52, 591–611. doi: 10.1093/biomet/52.3-4.591

Shen, L., Margolies, L. R., Rothstein, J. H., Fluder, E., McBride, R., and Sieh, W. (2019). Deep learning to improve breast cancer detection on screening mammography. *Sci. Rep.* 9, 1–12. doi: 10.1038/s41598-019-48995-4

Shorten, C., and Khoshgoftaar, T. M. (2019). A survey on image data augmentation for deep learning. *J. Big Data* 6, 1–48. doi: 10.1186/s40537-019-0197-0

Sokolova, M., and Lapalme, G. (2009). A systematic analysis of performance measures for classification tasks. *Inform. Proc. Manage.* 45, 427-437. doi: 10.1016/j.ipm.2009.03.002

Stupple, A., Singerman, D., and Celi, L. A. (2019). The reproducibility crisis in the age of digital medicine. *NPJ Digit. Med.* 2, 1–3. doi: 10.1038/s41746-019-0079-z

Tan, M., and Le, Q. (2019). "Efficientnet: Rethinking model scaling for convolutional neural networks," in *International Conference on Machine Learning* (New York: PMLR), 6105–6114.

Tong, T., Wolz, R., Gao, Q., Guerrero, R., Hajnal, J. V., Rueckert, D., et al. (2014). Multiple instance learning for classification of dementia in brain mri. *Med. Image Anal.* 18, 808–818. doi: 10.1016/j.media.2014.04.006

Van De Pol, L. A., Hensel, A., van der Flier, W. M., Visser, P. J., Pijnenburg, Y. A., Barkhof, F., et al. (2006). Hippocampal atrophy on mri in frontotemporal lobar degeneration and alzheimer's disease. *J. Neurol. Neurosurg. Psychiat.* 77, 439–442. doi: 10.1136/jnnp.2005.075341

Van der Maaten, L., and Hinton, G. (2008). Visualizing data using t-SNE. J. Mach. Learn. Res. 9:11.

Vento, D. D., and Fanfarillo, A. (2019). "Traps, pitfalls and misconceptions of machine learning applied to scientific disciplines," in *Proceedings of the Practice and Experience in Advanced Research Computing on Rise of the Machines (Learning)* (New York; NY: Association for Computing Machinery), 1–8.

Wen, J., Thibeau-Sutre, E., Diaz-Melo, M., Samper-González, J., Routier, A., Bottani, S., et al. (2020). Convolutional neural networks for classification of alzheimer's disease: Overview and reproducible evaluation. *Med. Image Anal.* 63:101694. doi: 10.1016/j.media.2020.101694

Wu, Y.-T., Beiser, A. S., Breteler, M. M., Fratiglioni, L., Helmer, C., Hendrie, H. C., et al. (2017). The changing prevalence and incidence of dementia over time-current evidence. *Nat. Rev. Neurol.* 13, 327–339. doi: 10.1038/nrneurol.2017.63

Xiao, Z., Ding, Y., Lan, T., Zhang, C., Luo, C., Qin, Z., et al. (2017). Brain mr image classification for Alzheimer's disease diagnosis based on multifeature fusion. *Comput. Math. Methods Med.* 2017:1952373. doi: 10.1155/2017/1952373

Yu, W., Lei, B., Wang, S., Liu, Y., Feng, Z., Hu, Y., et al. (2022). Morphological feature visualization of alzheimer's disease via multidirectional perception gan. *IEEE Trans. Neural Netw. Learn. Syst.* 34, 4401–4415. doi: 10.1109/TNNLS.2021.3118369

Yue, L., Gong, X., Li, J., Ji, H., Li, M., and Nandi, A. K. (2019). Hierarchical feature extraction for early alzheimer's disease diagnosis. *IEEE Access* 7, 93752–93760. doi: 10.1109/ACCESS.2019.2926288

Zhang, C., Bengio, S., Hardt, M., Recht, B., and Vinyals, O. (2021). Understanding deep learning (still) requires rethinking generalization. *Commun. ACM* 64, 107–115. doi: 10.1145/3446776

Zong, Y., Zuo, Q., Ng, M. K.-P., Lei, B., and Wang, S. (2024). A new brain network construction paradigm for brain disorder via diffusion-based graph contrastive learning. *IEEE Trans. Pattern Analy. Mach. Intellig.* doi: 10.1109/TPAMI.2024.3442811

Zuo, Q., Wu, H., Chen, C. P., Lei, B., and Wang, S. (2024). Prior-guided adversarial learning with hypergraph for predicting abnormal connections in Alzheimer's disease. *IEEE Trans. Cybernet*. doi: 10.1109/TCYB.2023.3344641